SCHEMBL2202074

SCHEMBL2202074

COCCN1CCN(C(=O)c2nn(C)c(-c3ccccc3-c3cc4ccccc4o3)c2C)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.47
DRD2 P14416 3/20 0.47
DRD3 P35462 3/20 0.47
PKM P14618 1/20 0.44
RAB9A P51151 2/20 0.42
NPC1 O15118 1/20 0.42
TSHR P16473 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
KDM4E B2RXH2 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
HPGD P15428 1/20 0.41
CYP2C19 P33261 1/20 0.41
HSD17B10 Q99714 1/20 0.41
PIK3CD O00329 4/20 0.40
PIK3R2 O00459 4/20 0.40
PIK3CA P42336 4/20 0.40
PIK3CB P42338 4/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2201258 0.90 ALDH1A1 (0.42) ALDH1A1DRD2DRD3RAB9ATSHR
SCHEMBL2201674 0.89 DRD3 (0.40) ALDH1A1DRD2DRD3RAB9ATSHR
SCHEMBL2202072 0.88 DRD2 (0.46) ALDH1A1DRD2DRD3PKMRAB9A
SCHEMBL2200712 0.87 GRIN2B (0.44) ALDH1A1DRD2DRD3RAB9ATSHR
SCHEMBL2197343 0.79 EIF4E (0.51) ALDH1A1RAB9ANPC1SMN1; SMN2MEN1
SCHEMBL2201254 0.78 ALDH1A1 (0.41) ALDH1A1DRD2DRD3RAB9ATSHR
SCHEMBL2199010 0.78 KDM4E (0.45) ALDH1A1RAB9ANPC1TSHRSMN1; SMN2
SCHEMBL2203144 0.78 MAPT (0.50) ALDH1A1RAB9ANPC1TSHRSMN1; SMN2
SCHEMBL3689666 0.77 POLR1A (0.41) ALDH1A1PKMRAB9ANPC1TSHR
SCHEMBL2201671 0.77 DRD3 (0.39) ALDH1A1DRD2DRD3RAB9ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7977358-B2 Pyrazol derivatives HOFFMANN-LA ROCHE INC. (US) 2011-07-12 US disclosed
EP-2182953-A2 NEW PYRAZOL DERIVATIVES F. Hoffmann-Roche AG (CH) 2010-05-12 EP disclosed
US-20090029963-A1 PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 US disclosed
WO-2009013211-A2 NEW PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090029963-A1 PYRAZOL DERIVATIVES CCR1, CCR3, CCRL2 ALDH1A1 1476/4885DRD2 1088/4885DRD3 751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.